Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Authors:
- Meral SeferoğluMSMeral Seferoğlu
- Bilge Piri ÇınarBÇBilge Piri Çınar
- Ülgen Yalaz TekanÜTÜlgen Yalaz Tekan
- Fatma AvşarFAFatma Avşar
- Pınar YiğitPYPınar Yiğit
- Ali Özhan SıvacıASAli Özhan Sıvacı
- Serkan DemirSDSerkan Demir
- Melih TütüncüMTMelih Tütüncü
- Haluk GümüşHGHaluk Gümüş
- Cihat UzunköprüCUCihat Uzunköprü
- Yeşim BeckmannYBYeşim Beckmann
- Gülşen Akman DemirGDGülşen Akman Demir
- 19 February 2025
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Abstract
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.Keywords
This publication has 34 references indexed in Scilit:
- Evaluation of adherence to treatment in patients with multiple sclerosis from Latin AmericaMultiple Sclerosis and Related Disorders, 2022
- A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in TurkeyMultiple Sclerosis and Related Disorders, 2021
- Perception of Multiple Sclerosis Impact and Treatment Efficacy Beliefs: Mediating Effect of Patient's Illness and Self-AppraisalsJournal of Pain and Symptom Management, 2019
- Adherence and persistence to drug therapies for multiple sclerosis: A population-based studyMultiple Sclerosis and Related Disorders, 2016
- Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi StudyNeurology and Therapy, 2015
- Treatment compliance with first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE StudyNeurología (English Edition), 2015
- Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapseMultiple Sclerosis and Related Disorders, 2015
- Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysisAdvances in Therapy, 2011
- Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdvances in Therapy, 2010
- Factors that influence adherence with disease-modifying therapy in MSJournal of Neurology, 2009